How can pharmaceutical companies turn patient experience data (PED) into decision-grade evidence? This insight brief examines EMA's evolving expectations for patient experience data and outlines a practical framework for designing, validating, and leveraging PED to support regulatory, HTA, and access-related decisions. Discover how proactive PED planning can strengthen evidence packages, improve cross-functional alignment, and enhance the impact of patient-centered evidence across global markets.